AIM ImmunoTech (AIM) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 11, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-27072
Entity Registrant Name	AIM IMMUNOTECH INC.
Entity Central Index Key	0000946644
Entity Tax Identification Number	52-0845822
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2117 SW Highway 484
Entity Address, City or Town	Ocala
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34473
City Area Code	352
Local Phone Number	448-7797
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AIM
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		47,848,622

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 41,142	$ 38,501
Marketable securities		501
Funds receivable from New Jersey net operating loss		1,090
Accounts receivable, net	28	34
Prepaid expenses and other current assets	155	184
Total current assets	41,325	40,310
Property and equipment, net	6,145	6,473
Right of use asset, net	157	179
Patent and trademark rights, net	1,783	1,498
Marketable securities, long term	16,135	15,376
Other assets	1,177	748
Total assets	66,722	64,584
Current liabilities:
Accounts payable	451	383
Accrued expenses	373	442
Current portion of operating lease liability	52	47
Current portion of financing obligation		230
Total current liabilities	876	1,102
Long-term liabilities:
Operating lease liability	105	132
Financing obligation arising from sale leaseback transaction (Note 13)		1,876
Redeemable warrants	209	180
Commitments and contingencies (Notes 11, 12, 13, and 14)
Stockholders’ equity:
Series B Convertible Preferred Stock, stated value $1,000 per share, 725 shares designated, 732 shares issued and outstanding	725	732
Common Stock, par value $0.001 per share, authorized 350,000,000 shares: issued and outstanding 47,832,997 and 42,154,371, respectively	48	42
Additional paid-in capital	416,435	402,541
Accumulated other comprehensive loss	(247)	(47)
Accumulated deficit	(351,429)	(341,974)
Total stockholders’ equity	65,532	61,294
Total liabilities and stockholders’ equity	$ 66,722	$ 64,584

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	47,832,997	42,154,371
Common stock, shares outstanding	47,832,997	42,154,371
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 1,000	$ 1,000
Preferred stock, shares designated	725	725
Preferred stock, shares, issued	732	732
Preferred stock, shares, outstanding	732	732

Consolidated Statement of Opera

Consolidated Statement of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues:
Total Revenues	$ 23	$ 40	$ 52	$ 85
Costs and Expenses:
Production costs	279	200	517	404
Research and development	1,317	1,463	2,742	2,343
General and administrative	2,145	1,717	4,256	3,986
Total Costs and Expenses	3,741	3,380	7,515	6,733
Operating loss	(3,718)	(3,340)	(7,463)	(6,648)
Interest and other income	51	46	120	67
Interest expense and other finance costs	(19)	(249)	(67)	(571)
Extinguishment of financing obligation and note payable	(2,701)	142	(2,701)	142
Gain on sale of fixed assets	216		216
Redeemable warrants valuation adjustment	7	31	(29)	(150)
Gain from sale of Income tax operating losses	288		469
Net Loss	(5,876)	(3,370)	(9,455)	(7,160)
Other comprehensive (loss)
Reclassification adjustment for realized investment loss	25		25
Change in unrealized loss on marketable securities available for sale	(62)	67	(225)	63
Comprehensive loss	$ (5,913)	$ (3,303)	$ (9,655)	$ (7,097)
Basic and diluted loss per share	$ (0.12)	$ (0.11)	$ (0.20)	$ (0.19)
Weighted average shares outstanding basic and diluted	47,832,997	29,970,197	46,805,492	37,073,765
UNITED STATES
Revenues:
Total Revenues	$ 23	$ 40	$ 52	$ 83
Europe [Member]
Revenues:
Total Revenues				$ 2

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 778	$ 10	$ 340,228		$ (328,109)	$ 12,907
Beginning balance, shares at Dec. 31, 2019		10,386,754
Common stock issuance, net of costs		$ 18	25,746			25,764
Common stock issuances, net of costs, shares		17,628,996
Warrant modification			46			46
Shares issued to pay accounts payable			10			10
Shares issued to pay accounts payable, shares		4,762
Equity-based compensation			196			196
Series B preferred shares converted to common shares	(9)		9
Comprehensive loss				(4)	(3,790)	(3,794)
Ending balance, value at Mar. 31, 2020	769	$ 28	366,235	(4)	(331,899)	35,129
Ending balance, shares at Mar. 31, 2020		28,020,512
Beginning balance, value at Dec. 31, 2019	778	$ 10	340,228		(328,109)	12,907
Beginning balance, shares at Dec. 31, 2019		10,386,754
Comprehensive loss						(7,097)
Ending balance, value at Jun. 30, 2020	737	$ 34	381,427	63	(335,269)	46,992
Ending balance, shares at Jun. 30, 2020		34,250,615
Beginning balance, value at Dec. 31, 2019	778	$ 10	340,228		(328,109)	12,907
Beginning balance, shares at Dec. 31, 2019		10,386,754
Ending balance, value at Dec. 31, 2020	732	$ 42	402,541	(47)	(341,974)	61,294
Ending balance, shares at Dec. 31, 2020		42,154,371
Beginning balance, value at Mar. 31, 2020	769	$ 28	366,235	(4)	(331,899)	35,129
Beginning balance, shares at Mar. 31, 2020		28,020,512
Common stock issuance, net of costs		$ 6	15,010			15,016
Common stock issuances, net of costs, shares		6,230,103
Equity-based compensation			150			150
Series B preferred shares converted to common shares	(32)		32
Comprehensive loss				67	(3,370)	(3,303)
Ending balance, value at Jun. 30, 2020	737	$ 34	381,427	63	(335,269)	46,992
Ending balance, shares at Jun. 30, 2020		34,250,615
Beginning balance, value at Dec. 31, 2020	732	$ 42	402,541	(47)	(341,974)	61,294
Beginning balance, shares at Dec. 31, 2020		42,154,371
Common stock issuance, net of costs		$ 6	12,881			12,887
Common stock issuances, net of costs, shares		5,678,626
Equity-based compensation			526			526
Series B preferred shares converted to common shares	(7)		7
Comprehensive loss				(163)	(3,579)	(3,742)
Ending balance, value at Mar. 31, 2021	725	$ 48	415,955	(210)	(345,553)	70,965
Ending balance, shares at Mar. 31, 2021		47,832,997
Beginning balance, value at Dec. 31, 2020	732	$ 42	402,541	(47)	(341,974)	61,294
Beginning balance, shares at Dec. 31, 2020		42,154,371
Comprehensive loss						(9,655)
Ending balance, value at Jun. 30, 2021	725	$ 48	416,435	(247)	(351,429)	65,532
Ending balance, shares at Jun. 30, 2021		47,832,997
Beginning balance, value at Mar. 31, 2021	725	$ 48	415,955	(210)	(345,553)	70,965
Beginning balance, shares at Mar. 31, 2021		47,832,997
Equity-based compensation			480			480
Comprehensive loss				(37)	(5,876)	(5,913)
Ending balance, value at Jun. 30, 2021	$ 725	$ 48	$ 416,435	$ (247)	$ (351,429)	$ 65,532
Ending balance, shares at Jun. 30, 2021		47,832,997

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (5,876)	$ (3,370)	$ (9,455)	$ (7,160)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment			325	340
Redeemable warrants valuation adjustment			29	150
Warrant modification				46
Extinguishment of financing obligation and note payable			2,701	142
Amortization of patent, trademark rights			80	67	$ 158
Changes in ROU assets			22	22
Gain on sale of property and equipment			(216)
Gain from sale of income tax operating losses	(288)		(469)
Equity-based compensation			1,006	346
Realized (loss) gain on sale of marketable securities			25	63
Amortization of finance and debt issuance costs			47	42
Change in assets and liabilities:
Accounts receivable			6	4
Funds Receivable from New Jersey net operating loss			1,090	770
Prepaid expenses and other current assets and other non-current assets			69	730
Lease liability			(22)	(22)
Accounts payable			68	(217)
Accrued interest expense				230
Accrued expenses			(69)	(78)
Net cash used in operating activities			(4,763)	(4,525)
Cash flows from investing activities:
Proceeds from sale of marketable securities			1,613	8,497
Purchase of marketable securities			(2,096)	(7,590)
Purchase of property and equipment			(26)	(9)
Proceeds from sale of property and equipment			245
Purchase of patent and trademark rights			(365)	(297)
Net cash (used in) provided by investing activities			(629)	601
Cash flows from financing activities:
Payment and note payable				(4,283)
Payment of financing obligation			(4,732)
Financing obligation payments			(122)	(176)
Proceeds from sale of stock, net of issuance costs			12,887	40,821
Net cash provided by financing activities			8,033	36,362
Net increase in cash and cash equivalents			2,641	32,438
Cash and cash equivalents at beginning of period			38,501	1,470	1,470
Cash and cash equivalents at end of period	$ 41,142	$ 33,908	41,142	33,908	$ 38,501
Supplemental disclosures of non-cash investing and financing cash flow information:
Stock issued to settle accounts payable				10
Unrealized loss on marketable securities			(225)	63
Conversion of Series B preferred			$ 7	$ 41

Business and Basis of Presentat

Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Note 1: Business and Basis of Presentation AIM ImmunoTech Inc. (collectively with its subsidiaries, “AIM” or the “Company”) is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers, viruses and immune-deficiency disorders. The Company has established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM’s flagship products include Ampligen® (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3). A first-in-class drug is also known as a new molecular entity that contains an active moiety. Ampligen has not been approved by the FDA or marketed in the United States. Since the outbreak of SARS-CoV-2, the novel virus that causes COVID-19, the Company has been actively engaged in determining whether Ampligen could be an effective treatment for this virus or could be part of a vaccine. The Company believes that Ampligen has the potential to be both an early-onset treatment for and prophylaxis against SARS-CoV-2. Ampligen also has potential as a COVID-19 vaccine strategy that combines Ampligen as an immune enhancer seeking to boost the efficacy of the vaccine and also convey cross-reactivity and cross-protection against future mutations. The Company believes that prior studies of Ampligen in SARS-CoV-1 animal experimentation may predict similar protective effects against the new virus. Given the evolution of uncertainty associated with SAR-CoV-2, there is uncertainty as to the effects on the Company’s financial position, results of operations or cash flows. The full impact of the COVID-19 pandemic continues to evolve, as such, it is uncertain as to the full magnitude that the pandemic will have on the Company’s financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation on its financial condition, liquidity, operations, scientific collaborations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its impact, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year 2021. Although the Company cannot estimate the length or gravity of the impact of the COVID-19 pandemic at this time, if the pandemic continues, it may have a material adverse effect on the Company’s results of future operations, financial position, and liquidity for the fiscal year 2021. (see Note 13: Financing Obligation Arising from Sale Leaseback Transaction). Beginning in April 2020, the Company entered into confidentiality and non-disclosure agreements with numerous companies for the potential outsourcing of the production of polymer, enzyme, placebo as well as Ampligen and one Contract Research Organization which may also assist with the planning, presentation and filing of documents with the FDA. These confidentiality and non-disclosure agreements are only the initial step in forging relationships with these entities to obtain contract manufacturers and research partners. No assurance can be given as to how many of these, initial explorations, if any, will result in definitive arrangements or, with regard to potential research partners, what research arrangements will develop and thereafter prove fruitful. Ampligen represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has in the clinic demonstrated the potential for standalone efficacy in a number of solid tumors. The Company has also seen success in increasing survival rates and efficacy in the treatment of animal tumors when Ampligen is used in combination with checkpoint blockade therapies. This success in the field of immuno-oncology has guided the Company’s focus toward the potential use of Ampligen as a combinational therapy for the treatment of a variety of solid tumor types. There are currently multiple Ampligen clinical trials testing Ampligen in humans — both underway and planned — at major cancer research centers. Ampligen was used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center. In September 2020, AIM reported receipt of statistically significantly results of positive survival benefit when using Ampligen in patients with locally advanced/metastatic pancreatic cancer after systemic chemotherapy. AIM will work with its Contract Research Organization, Amarex Clinical Research LLC, to seek FDA “fast-track” and possibly even FDA “breakthrough” designations and to obtain authorization to conduct follow-up pancreatic cancer Phase 2/3 clinical trials with potential sites in the Netherlands at Erasmus MC under Prof. van Eijck, and also at major cancer research centers in the United States. Ampligen is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). AIM is currently sponsoring an expanded access program for ME/CFS patients in the U.S. In August 2016, the Company received approval of its New Drug Application, or NDA from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) for commercial sale of Ampligen in the Argentine Republic for the treatment of severe CFS. With regulatory approval in Argentina, Ampligen is the world’s only approved therapeutic for ME/CFS. Shipment of the drug product to Argentina was initiated in 2018 to complete the release testing by ANMAT needed for commercial distribution. On September 19, 2019, we received clearance from the FDA to ship Ampligen to Argentina for the commercial launch and subsequent sales. On June 10, 2020, the Company received import clearance from ANMAT to import the first shipment of commercial grade vials of Ampligen to Argentina. The next steps in the commercial launch of Ampligen include ANMAT conducting a final inspection of the product and release tests before granting final approval to begin commercial sales. Progress in Argentina is delayed, due to pandemic factors. The ongoing impact of COVID-19 in Argentina is taxing the nation’s health care system and is, understandably, the main priority of its regulators. AIM has supplied GP Pharm with the Ampligen required for testing and ANMAT release. Once final approval by ANMAT is obtained, the Company anticipates that GP Pharm will begin distributing Ampligen in Argentina. The Company continues to pursue its Ampligen NDA, for the treatment of CFS, with the FDA. Alferon N Injection is approved for a category of sexually transmitted disease infections and patients that are intolerant to recombinant interferon in Argentina. Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment) or recurring external condylomata acuminata/genital warts (GW) in patients 18 years of age or older. Certain types of human papilloma viruses cause GW. AIM also has approval from ANMAT for the treatment of refractory patients that failed or were intolerant to treatment with recombinant interferon in Argentina. The Company owns and operates a 30,000 On April 5, 2021, the Company’s board of directors approved the exercise of AIM’s option to re-purchase the New Brunswick facility, pursuant to the terms of the March 16, 2018, sale and lease-back agreement and, thereafter, the Company sold certain equipment and machinery that it determined to be obsolete and no longer needed for current and future manufacturing. The buy-back purchase was completed in May 2021. (see Note 13: Financing Obligation Arising from Sale Leaseback Transaction). In the opinion of management, all adjustments necessary for a fair presentation of such consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year. The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2020, and 2019, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 31, 2021.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	Note 2: Net Loss Per Share Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 1,621,928 526,266

Equity-Based Compensation

Equity-Based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Equity-Based Compensation	Note 3: Equity-Based Compensation The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. There were no Stock option for employees’ activity during the six months ended June 30, 2021, is as follows: Stock option activity for employees: Schedule of Stock Option Activity Number of Weighted Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2021 1,049,695 $ 5.38 9.28 $ — Granted — — — — Forfeited (50,898 ) 2.39 — — Expired — — — — Outstanding June 30, 2021 998,797 $ 5.53 9.23 $ — Vested and expected to vest June 30, 2021 998,797 $ 5.53 9.23 $ — Exercisable June 30, 2021 725,198 $ 4.07 8.10 $ — Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Unvested January 1, 2021 767,029 $ 3.71 9.68 $ — Granted — — — — Expired (50,898 ) 2.39 — — Vested (442,532 ) 2.47 — — Unvested June 30, 2021 273,599 $ 13.99 7.33 $ — Stock option activity for non-employees: Schedule of Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2021 166,533 $ 11.03 6.88 $ — Granted — — — — Forfeited — — — — Expired (322 ) 965.93 — — Outstanding June 30, 2021 166,211 $ 9.18 7.05 $ — Vested and expected to vest June 30, 2021 166,211 $ 9.18 7.05 $ — Exercisable June 30, 2021 155,766 $ 4.07 7.74 $ — Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Unvested January 1, 2021 66,202 $ 7.24 6.38 $ — Granted — — — — Expired — — — — Vested (55,757 ) 4.69 — — Unvested June 30, 2021 10,445 $ 20.86 6.25 $ — Stock-based compensation expense was approximately $ 1,006 346 As of June 30, 2021, and 2020, respectively, there was approximately $ 434 442

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Note 4: Marketable Securities Marketable securities consist of debt securities. As of June 30, 2021, and December 31, 2020, it was determined that none of the marketable securities had an other-than-temporary impairment. As of June 30, 2021, and December 31, 2020, all securities were measured as Level 1 instruments of the fair value measurements standard (see Note 12: Fair Value). As of June 30, 2021, and December 31, 2020, the Company held $ 16,135 15,877 Debt securities classified as available for sale consisted of: Schedule of Available for Sale June 30, 2021 (in thousands) Securities Amortized Cost Gross Unrealized Gains /(Losses) Fair Value Marketable Securities U.S. Treasury notes $ 5,502 $ (76 ) $ 5,426 $ 5,426 U.S. Government mortgage-backed securities 4,401 288 4,689 4,689 Corporate bonds 6,432 (412 ) 6,020 6,020 Totals $ 16,335 $ (200 ) $ 16,135 $ 16,135 December 31, 2020 (in thousands) Securities Amortized Cost Gross Unrealized Gains /(Losses) Fair Value Marketable Securities U.S. Treasury notes $ 5,746 $ (47 ) $ 5,699 $ 5,699 U.S. Government mortgage-backed securities 4,890 (52 ) 4,838 4,838 Corporate bonds 5,288 52 5,340 5,340 Totals $ 15,924 $ (47 ) $ 15,877 $ 15,877 The following presents available-for-sale securities’ gross unrealized losses and fair value aggregated by the short- and long-term maturity. June 30, 2021 (in thousands) 12 Months or More Total Securities Fair Value Gross Fair Value Gross U.S. Treasury notes $ 5,502 $ (76 ) $ 5,426 $ (76 ) U.S. Government mortgage-backed securities 4,401 288 4,689 288 Corporate bonds 6,432 (412 ) 6,020 (412 ) Totals $ 16,335 $ (200 ) $ 16,135 $ (200 ) December 31, 2020 (in thousands) Less than 12 Months 12 Months or More Total Securities Fair Value Gross Fair Value Gross Fair Value Gross U.S. Treasury notes $ 501 $ — $ 5,245 $ (47 ) $ 5,699 $ (47 ) U.S. Government mortgage-backed securities — — 4,890 (52 ) 4,838 (52 ) Corporate bonds — — 5,288 52 5,340 52 Totals $ 501 $ — $ 15,423 $ (47 ) $ 15,877 $ (47 )

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
Accrued Expenses	Note 5: Accrued Expenses Accrued expenses consist of the following: Schedule of Accrued Expenses (in thousands) June 30, 2021 December 31, 2020 Compensation $ 16 $ 2 Professional fees 180 124 Other expenses 177 316 Accrued expenses $ 373 $ 442

Property and Equipment, net

Property and Equipment, net	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Note 6: Property and Equipment, net Schedule of Property and Equipment (in thousands) June 30, 2021 December 31, 2020 Land, buildings and improvements $ 10,530 $ 10,547 Furniture, fixtures, and equipment 2,426 5,136 Total property and equipment 12,956 15,683 Less: accumulated depreciation (6,811 ) (9,210 ) Property and equipment, net $ 6,145 $ 6,473 Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three to thirty-nine years. On March 16, 2018, the Company sold land and a building for $ 4,080 and concurrently entered into an agreement to lease the property back for ten years. The lease payments are initially $ 408 (See Note 13: Financing Obligation Arising from Sale Leaseback Transaction for more details on the sale leaseback of the property and equipment). On May 13, 2021, the Company completed its re-purchase of the land and building for $ 4,732,637 In April 2021, the Company sold some of the assets located at its facility at 783 Jersey Ave., New Brunswick, N.J. The assets sold consist of equipment and machinery that the Company determined to be obsolete and no longer needed for current and future manufacturing. The assets were sold for an aggregate of $ 245 216

Patents

Patents	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 7: Patents Schedule of Patents, Trademark Rights (in thousands) December 31, 2019 $ 1,151 Acquisitions 573 Abandonments (68 ) Amortization (158 ) December 31, 2020 $ 1,498 Acquisitions 365 Amortization (80 ) June 30, 2021 $ 1,783 Patents and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method of the estimated useful life of 17 Amortization of patents and trademarks for each of the next five years is as follows: Schedule of Amortization of Patents and Trademarks Year Ending December 31, (in thousands) 2021 $ 125 2022 137 2023 154 2024 180 2025 212 Thereafter 975 Total $ 1,783

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Stockholders’ Equity	Note 8: Stockholders’ Equity (a) Preferred Stock The Company is authorized to issue 5,000,000 0.01 250,000 1,000 The Company is authorized to issue 8,000 Series B Convertible Preferred Stock, no par value, stated value $1,000 per share. As of June 30, 2021, and December 31, 2020, the Company had 725 732 114 Pursuant to a registration statement relating to a rights offering declared effective by the SEC on February 14, 2019, AIM distributed to its holders of common stock and to holders of certain options and warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase one unit, at a subscription price of $ 1,000 1,000 8.80 114 8.80 five years 4,700 (b) Common Stock The Company has authorized shares of 350,000,000 8,000,000 On July 7, 2020, the board of directors approved a plan pursuant to which all directors, officers, and employees could purchase from the company up to an aggregate of $ 500 10,730 2.33 25 500 During the fiscal year ended December 31, 2020, the Company issued a total of 27,501 1.72 2.03 50 During the six months ended June 30, 2021, the Company issued a total of 21,700 2.26 2.35 50 On September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the “Offering”) of (i) 1,740,550 7,148,310 8,888,860 a Representative’s Warrant to purchase up to an aggregate of 266,665 . The shares of Common Stock and Warrants were sold at a combined Offering price of $ 0.90 Each Warrant sold with the shares of Common Stock represents the right to purchase one share of Common Stock at an exercise price of $0.99 per share. The Pre-Funded Warrants and Warrants were sold at a combined Offering price of $0.899, less underwriting discounts and commissions. The Pre-Funded Warrants were sold to purchasers whose purchase of shares of Common Stock in the Offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of the Company’s outstanding Common Stock immediately following the consummation of the Offering, in lieu of shares of Common Stock. Each Pre-Funded Warrant represents the right to purchase one share of Common Stock at an exercise price of $0.001 per share. 7,200 , 2020, 1,870,000 7,687,860 In addition, on March 25, 2020, the Representative’s Warrant was amended to permit exercise of such warrant to commence on March 30, 2020. These warrants were exercised on March 31, 2020, and an aggregate of 266,665 264 46 On July 19, 2019, the Company entered into a new Equity Distribution Agreement (the “2019 EDA”) with Maxim Group LLC (“Maxim”), pursuant to which it could sell from time to time, shares of its Common Stock through Maxim, as agent (the “Offering”). The 2019 EDA replaced a prior EDA with Maxim. For the year ended December 31, 2020, the Company sold 20,444,807 53,936,615 3.5 1,888,727 5,665,731 13,301,526 3.5% 465,533 The 2018 Equity Incentive Plan, effective September 12, 2018, authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards. Initially, a maximum of 7,000,000 26,324 9.68 10 23 9.68 ten years 27,570 9.68 ten years one year 400,000 2.77 3.07 ten years one year 675,000 1.85 1.96 ten years one year As of June 30, 2021, and December 31, 2020, there were 47,832,997 42,154,371

Cash and Cash Equivalents

Cash and Cash Equivalents	6 Months Ended
	Jun. 30, 2021
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Note 9 Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2021
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	Note 10: Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, “Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)” .

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Long-Term Debt	Note 11: Long-Term Debt On August 5, 2019, the Company issued a Secured Promissory Note (the “CV Note”) with Chicago Venture Partners, L.P. (the “CV”). The Note has an original principal amount of $ 2,635 10% 24 1,900 During the quarter ending June 30, 2020, the Holder made redemptions of $ 650 1,985 220 1,795 369 6 66 Interest expense associated with the CV Note was approximately $ 0 116 On December 5, 2019, the Company issued a secured Promissory Note (the “AS Note”) to Atlas Sciences L.P. (“AS”). The AS Note has an original principal amount of $ 2,175 10% 24 On June 19, 2020, the Company paid off the outstanding AS note which consisted of original principal of $ 2,175 122 376 7 1,838 76 Interest expense associated with AS Note for the period ending June 30, 2021, was $ 0 106

Fair Value

Fair Value	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value	Note 12: Fair Value The Company is required under U.S. GAAP to disclose information about the fair value of all the Company’s financial instruments, whether or not these instruments are measured at fair value on the Company’s consolidated balance sheets. The Company estimates that the fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to the short-term maturities of these items. The Company also has certain warrants with a cash settlement feature in the unlikely occurrence of a Fundamental Transaction, namely (1) a merger or consolidation with another person; (2) sale of substantially all of its assets; (3) holders of common stock sell 50% or more of outstanding shares; (4) the Company effects an exchange of all its securities for other securities, cash or property, and (5) the Company effects a stock purchase agreement or business combination for more than 50% of outstanding shares. The Company recomputes the fair value of the Warrants at the issuance date and the end of each quarterly reporting period. Such value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions or the numbers input based on such assumptions, the resulting fair value could be materially different. The Company utilized the following assumptions to estimate the fair value of the August 2016 Warrants: Schedule of Assumptions to Estimate Fair Value of Warrants June 30, 2021 December 31, 2020 Underlying price per share $ 2.15 $ 1.79 Exercise price per share $ 82.50 $ 82.50 Risk-free interest rate 0.02 % 0.09 % Expected holding period 0.17 0.67 Expected volatility 35 % 75 % Expected dividend yield - - The Company utilized the following assumptions to estimate the fair value of the February 2017 Warrants: June 30, 2021 December 31, 2020 Underlying price per share $ 2.15 $ 1.79 Exercise price per share $ 30.25 33.00 $ 30.25 33.00 Risk-free interest rate 0.08 0.10 % 0.12 % Expected holding period 1.09 1.10 1.58 1.60 Expected volatility 80 % 130 % Expected dividend yield - - The Company utilized the following assumptions to estimate the fair value of the June 2017 Warrants: June 30, 2021 December 31, 2020 Underlying price per share $ 2.15 $ 1.79 Exercise price per share $ 27.50 $ 27.50 Risk-free interest rate 0.07 % 0.11 % Expected holding period 0.92 12.42 Expected volatility 75 % 135 % Expected dividend yield - - The Company utilized the following assumptions to estimate the fair value of the August 2017 Warrants: June 30, 2021 December 31, 2020 Underlying price per share $ 2.15 $ 1.79 Exercise price per share 19.80 $ 19.80 Risk-free interest rate 0.06 % 0.11 % Expected holding period 0.68 1.18 Expected volatility 70 % 110 % Expected dividend yield - - The Company utilized the following assumptions to estimate the fair value of the April 2018 Warrants: June 30, 2021 December 31, 2020 Underlying price per share $ 2.15 $ 1.79 Exercise price per share $ 17.16 $ 17.16 Risk-free interest rate 0.32 % 0.16 % Expected holding period 2.32 2.81 Expected volatility 140 % 105 % Expected dividend yield - - The Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants: June 30, 2021 December 31, 2020 Underlying price per share $ 2.15 $ 1.79 Exercise price per share $ 8.80 $ 8.80 Risk-free interest rate 0.29 % 0.19 % Expected holding period 2.69 3.19 Expected volatility 135 % 105 % Expected dividend yield - - The significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are: (i) Risk-Free Interest Rate (ii) Expected Holding Period (iii) Expected Volatility (iv) Expected Dividend Yield 0.00 (v) Expected Probability of a Fundamental Transaction. a. The Company only has one product that is FDA approved but which will not be available for commercial sales for 18 months at the earliest; b. The Company flagship product is approved only in Argentina for Severely Debilitated Chronic Fatigue Syndrome patients; c. The Company may have to perform additional clinical trials for FDA approval of its flagship product; d. Industry and global market conditions continue to include uncertainty, adding risk to any transaction; e. Available capital for a potential buyer in a cash transaction continues to be limited; f. The nature of a life science company is heavily dependent on future funding and high costs, including research & development; g. The Company has minimal revenue streams which could be insufficient to meet the funding needs for the cost of operations or construction at their manufacturing facility; and h. The Company’s Rights Agreement and Executive Agreements make it less attractive to a potential buyer. With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as: Schedule of Range of Probabilities Range of Probability Probability Low 0.5 % Medium 1.0 % High 5.0 % The Monte Carlo Simulation has incorporated a 5.0% probability of a Fundamental Transaction to date for the life of the securities. (vi) Expected Timing of Announcement of a Fundamental Transaction. (vii) Expected 100 Day Volatility at Announcement of a Fundamental Transaction 100% (viii) Expected Risk-Free Interest Rate at Announcement of a Fundamental Transaction (ix) Expected Time Between Announcement and Consummation of a Fundamental Transaction. While the assumptions remain consistent from period to period (e.g., using historical stock prices), the numbers input change from period to period (e.g., the actual historical prices input for the relevant period). The Company applies FASB ASC 820 that defines fair value, establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. The guidance does not impose any new requirements around which assets and liabilities are to be measured at fair value, and instead applies to asset and liability balances required or permitted to be measured at fair value under existing accounting pronouncements. The Company measures its warrant liability for those warrants with a cash settlement feature at fair value. FASB ASC 820-10-35-37 establishes a valuation hierarchy based on the transparency of inputs used in the valuation of an asset or liability. Classification is based on the lowest level of inputs that is significant to the fair value measurement. The valuation hierarchy contains three levels: ● Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes certain U.S. and government agency debt and equity securities that are traded in an active market. ● Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market. ● Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. As of June 30, 2021, the Company has classified the warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing these warrants. The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as: Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (in thousands) As of June 30, 2021 Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 16,135 $ 16,135 $ — $ — Liabilities: Redeemable warrants $ 209 — — $ 209 (in thousands) Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 15,877 $ 15,877 $ — $ — Liabilities: Redeemable warrants $ 180 — — $ 180 The changes in Level 3 Liabilities measured at fair value on a recurring basis are summarized as follows (in thousands): Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis Redeemable warrants: Balance at December 31, 2020 $ 180 Fair value adjustment 29 Balance at June 30, 2021 $ 209

Financing Obligation Arising fr

Financing Obligation Arising from Sale Leaseback Transaction	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Financing Obligation Arising from Sale Leaseback Transaction	Note 13: Financing Obligation Arising from Sale Leaseback Transaction On March 16, 2018, the Company sold land and a building for $ 4,080 lease the property back for ten years at $ 408 five years 3,225,806 0.3875 125% 4.99% On May 13, 2021, the Company completed its repurchase of the property for cash of $ 4,732,637 For the three months ended June 30, 2021, the loss on extinguishment was $ 2,701,460 19 31

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Leases	Note 14: Leases The Company entered into a Lease Agreement for a term of five years September 14, 2020 1,415 On June 13, 2018, the Company entered into a Lease Agreement for a term of six years July 1, 2018 3,000 3% 2,100 2,785 On May 1, 2019, the Company entered into a Lease Agreement for a term of three years May 1, 2019 3,000 1,500 The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably certain that the Company would exercise such options. The Company’s leases have remaining lease terms between 6 4 3.22 The Company has determined that the incremental borrowing rate is 10% as of June 30, 2021, based upon the most recently completed financing transaction in December 2019. Schedule of Operating lease Future Payments Year Ending June 30, (in thousands) 2021 $ 39 2022 50 2023 40 2024 46 2025 16 Thereafter 7 Less imputed interest (41 ) Total $ 157 As of June 30, 2021, the balance of the right of use assets was $ 157 157 22 21

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 15: Subsequent Events None.

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Employees [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Schedule of Stock Option Activity	Stock option activity for employees: Schedule of Stock Option Activity Number of Weighted Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2021 1,049,695 $ 5.38 9.28 $ — Granted — — — — Forfeited (50,898 ) 2.39 — — Expired — — — — Outstanding June 30, 2021 998,797 $ 5.53 9.23 $ — Vested and expected to vest June 30, 2021 998,797 $ 5.53 9.23 $ — Exercisable June 30, 2021 725,198 $ 4.07 8.10 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Unvested January 1, 2021 767,029 $ 3.71 9.68 $ — Granted — — — — Expired (50,898 ) 2.39 — — Vested (442,532 ) 2.47 — — Unvested June 30, 2021 273,599 $ 13.99 7.33 $ —
Non Employees [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Schedule of Stock Option Activity	Stock option activity for non-employees: Schedule of Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2021 166,533 $ 11.03 6.88 $ — Granted — — — — Forfeited — — — — Expired (322 ) 965.93 — — Outstanding June 30, 2021 166,211 $ 9.18 7.05 $ — Vested and expected to vest June 30, 2021 166,211 $ 9.18 7.05 $ — Exercisable June 30, 2021 155,766 $ 4.07 7.74 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Unvested January 1, 2021 66,202 $ 7.24 6.38 $ — Granted — — — — Expired — — — — Vested (55,757 ) 4.69 — — Unvested June 30, 2021 10,445 $ 20.86 6.25 $ —

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Schedule of Available for Sale	Debt securities classified as available for sale consisted of: Schedule of Available for Sale June 30, 2021 (in thousands) Securities Amortized Cost Gross Unrealized Gains /(Losses) Fair Value Marketable Securities U.S. Treasury notes $ 5,502 $ (76 ) $ 5,426 $ 5,426 U.S. Government mortgage-backed securities 4,401 288 4,689 4,689 Corporate bonds 6,432 (412 ) 6,020 6,020 Totals $ 16,335 $ (200 ) $ 16,135 $ 16,135 December 31, 2020 (in thousands) Securities Amortized Cost Gross Unrealized Gains /(Losses) Fair Value Marketable Securities U.S. Treasury notes $ 5,746 $ (47 ) $ 5,699 $ 5,699 U.S. Government mortgage-backed securities 4,890 (52 ) 4,838 4,838 Corporate bonds 5,288 52 5,340 5,340 Totals $ 15,924 $ (47 ) $ 15,877 $ 15,877 The following presents available-for-sale securities’ gross unrealized losses and fair value aggregated by the short- and long-term maturity. June 30, 2021 (in thousands) 12 Months or More Total Securities Fair Value Gross Fair Value Gross U.S. Treasury notes $ 5,502 $ (76 ) $ 5,426 $ (76 ) U.S. Government mortgage-backed securities 4,401 288 4,689 288 Corporate bonds 6,432 (412 ) 6,020 (412 ) Totals $ 16,335 $ (200 ) $ 16,135 $ (200 ) December 31, 2020 (in thousands) Less than 12 Months 12 Months or More Total Securities Fair Value Gross Fair Value Gross Fair Value Gross U.S. Treasury notes $ 501 $ — $ 5,245 $ (47 ) $ 5,699 $ (47 ) U.S. Government mortgage-backed securities — — 4,890 (52 ) 4,838 (52 ) Corporate bonds — — 5,288 52 5,340 52 Totals $ 501 $ — $ 15,423 $ (47 ) $ 15,877 $ (47 )

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following: Schedule of Accrued Expenses (in thousands) June 30, 2021 December 31, 2020 Compensation $ 16 $ 2 Professional fees 180 124 Other expenses 177 316 Accrued expenses $ 373 $ 442

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Schedule of Property and Equipment (in thousands) June 30, 2021 December 31, 2020 Land, buildings and improvements $ 10,530 $ 10,547 Furniture, fixtures, and equipment 2,426 5,136 Total property and equipment 12,956 15,683 Less: accumulated depreciation (6,811 ) (9,210 ) Property and equipment, net $ 6,145 $ 6,473

Patents (Tables)

Patents (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents, Trademark Rights	Schedule of Patents, Trademark Rights (in thousands) December 31, 2019 $ 1,151 Acquisitions 573 Abandonments (68 ) Amortization (158 ) December 31, 2020 $ 1,498 Acquisitions 365 Amortization (80 ) June 30, 2021 $ 1,783
Schedule of Amortization of Patents and Trademarks	Amortization of patents and trademarks for each of the next five years is as follows: Schedule of Amortization of Patents and Trademarks Year Ending December 31, (in thousands) 2021 $ 125 2022 137 2023 154 2024 180 2025 212 Thereafter 975 Total $ 1,783

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Assumptions to Estimate Fair Value of Warrants	The Company utilized the following assumptions to estimate the fair value of the August 2016 Warrants: Schedule of Assumptions to Estimate Fair Value of Warrants June 30, 2021 December 31, 2020 Underlying price per share $ 2.15 $ 1.79 Exercise price per share $ 82.50 $ 82.50 Risk-free interest rate 0.02 % 0.09 % Expected holding period 0.17 0.67 Expected volatility 35 % 75 % Expected dividend yield - - The Company utilized the following assumptions to estimate the fair value of the February 2017 Warrants: June 30, 2021 December 31, 2020 Underlying price per share $ 2.15 $ 1.79 Exercise price per share $ 30.25 33.00 $ 30.25 33.00 Risk-free interest rate 0.08 0.10 % 0.12 % Expected holding period 1.09 1.10 1.58 1.60 Expected volatility 80 % 130 % Expected dividend yield - - The Company utilized the following assumptions to estimate the fair value of the June 2017 Warrants: June 30, 2021 December 31, 2020 Underlying price per share $ 2.15 $ 1.79 Exercise price per share $ 27.50 $ 27.50 Risk-free interest rate 0.07 % 0.11 % Expected holding period 0.92 12.42 Expected volatility 75 % 135 % Expected dividend yield - - The Company utilized the following assumptions to estimate the fair value of the August 2017 Warrants: June 30, 2021 December 31, 2020 Underlying price per share $ 2.15 $ 1.79 Exercise price per share 19.80 $ 19.80 Risk-free interest rate 0.06 % 0.11 % Expected holding period 0.68 1.18 Expected volatility 70 % 110 % Expected dividend yield - - The Company utilized the following assumptions to estimate the fair value of the April 2018 Warrants: June 30, 2021 December 31, 2020 Underlying price per share $ 2.15 $ 1.79 Exercise price per share $ 17.16 $ 17.16 Risk-free interest rate 0.32 % 0.16 % Expected holding period 2.32 2.81 Expected volatility 140 % 105 % Expected dividend yield - - The Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants: June 30, 2021 December 31, 2020 Underlying price per share $ 2.15 $ 1.79 Exercise price per share $ 8.80 $ 8.80 Risk-free interest rate 0.29 % 0.19 % Expected holding period 2.69 3.19 Expected volatility 135 % 105 % Expected dividend yield - -
Schedule of Range of Probabilities	With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as: Schedule of Range of Probabilities Range of Probability Probability Low 0.5 % Medium 1.0 % High 5.0 %
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as: Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (in thousands) As of June 30, 2021 Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 16,135 $ 16,135 $ — $ — Liabilities: Redeemable warrants $ 209 — — $ 209 (in thousands) Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 15,877 $ 15,877 $ — $ — Liabilities: Redeemable warrants $ 180 — — $ 180
Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis	The changes in Level 3 Liabilities measured at fair value on a recurring basis are summarized as follows (in thousands): Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis Redeemable warrants: Balance at December 31, 2020 $ 180 Fair value adjustment 29 Balance at June 30, 2021 $ 209

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Schedule of Operating lease Future Payments	The Company has determined that the incremental borrowing rate is 10% as of June 30, 2021, based upon the most recently completed financing transaction in December 2019. Schedule of Operating lease Future Payments Year Ending June 30, (in thousands) 2021 $ 39 2022 50 2023 40 2024 46 2025 16 Thereafter 7 Less imputed interest (41 ) Total $ 157

Business and Basis of Present_2

Business and Basis of Presentation (Details Narrative)	Jun. 30, 2021ft²
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Area of land	30,000

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,621,928	526,266
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,621,928	526,266

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Employees [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of Options, Granted
Number of Options, Expired	50,898
Number of Options, Expired	(50,898)
Stock Options [Member] | Employees [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of Options Outstanding, Beginning of Period	1,049,695
Weighted Average Exercise Price Outstanding, Beginning of Period | $ / shares	$ 5.38
Weighted Average Remaining Contracted Term (years) Outstanding, Beginning of Period	9 years 3 months 10 days
Aggregate Intrinsic Value Outstanding, Beginning of Period | $
Number of Options, Granted
Weighted Average Exercise Price, Granted | $ / shares
Aggregate Intrinsic Value, Granted | $
Number of Options, Forfeited	(50,898)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 2.39
Aggregate Intrinsic Value Outstanding, Ending of Period | $
Number of Options, Expired
Weighted Average Exercise Price, Expired | $ / shares
Aggregate Intrinsic Value, Forfeited | $
Number of Options Outstanding, Ending of Period	998,797
Weighted Average Exercise Price Outstanding, End of Period | $ / shares	$ 5.53
Weighted Average Remaining Contracted Term (years) Outstanding, End of Period	9 years 2 months 23 days
Aggregate Intrinsic Value Outstanding, Ending of Period | $
Number of Options, Vested and Expected to Vest	998,797
Weighted Average Exercise Price, Vested and Expected to Vest | $ / shares	$ 5.53
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest	9 years 2 months 23 days
Aggregate Intrinsic Value, Vested and Expected to Vest | $
Number of Options Exercisable, End of Period	725,198
Weighted Average Exercise Price Exercisable, Ending of Period | $ / shares	$ 4.07
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	8 years 1 month 6 days
Aggregate Intrinsic Value, Exercisable at End of Period | $
Number of Options, Forfeited	50,898
Number of Options, Expired
Stock Options [Member] | Non Employees [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of Options Outstanding, Beginning of Period	166,533
Weighted Average Exercise Price Outstanding, Beginning of Period | $ / shares	$ 11.03
Weighted Average Remaining Contracted Term (years) Outstanding, Beginning of Period	6 years 10 months 17 days
Aggregate Intrinsic Value Outstanding, Beginning of Period | $
Number of Options, Granted
Weighted Average Exercise Price, Granted | $ / shares
Aggregate Intrinsic Value, Granted | $
Number of Options, Forfeited
Weighted Average Exercise Price, Forfeited | $ / shares
Aggregate Intrinsic Value Outstanding, Ending of Period | $
Number of Options, Expired	322
Weighted Average Exercise Price, Expired | $ / shares	$ 965.93
Aggregate Intrinsic Value, Forfeited | $
Number of Options Outstanding, Ending of Period	166,211
Weighted Average Exercise Price Outstanding, End of Period | $ / shares	$ 9.18
Weighted Average Remaining Contracted Term (years) Outstanding, End of Period	7 years 18 days
Aggregate Intrinsic Value Outstanding, Ending of Period | $
Number of Options, Vested and Expected to Vest	166,211
Weighted Average Exercise Price, Vested and Expected to Vest | $ / shares	$ 9.18
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest	7 years 18 days
Aggregate Intrinsic Value, Vested and Expected to Vest | $
Number of Options Exercisable, End of Period	155,766
Weighted Average Exercise Price Exercisable, Ending of Period | $ / shares	$ 4.07
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	7 years 8 months 26 days
Aggregate Intrinsic Value, Exercisable at End of Period | $
Number of Options, Forfeited
Aggregate Intrinsic Value, Forfeited | $
Number of Options, Expired	(322)

Schedule of Unvested Stock Opti

Schedule of Unvested Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Employees [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Number of Options Unvested, Beginning of Period	767,029
Weighted Average Exercise Price Unvested, Beginning of Period | $ / shares	$ 3.71
Average Remaining Contractual Term (years) Unvested, Beginning of Period	9 years 8 months 4 days
Aggregate Intrinsic Value Unvested, Beginning of Period | $
Number of Options, Granted
Weighted Average Exercise Price, Granted | $ / shares
Aggregate Intrinsic Value, Granted | $
Number of Options, Expired	(50,898)
Weighted Average Exercise Price, Expired | $ / shares	$ 2.39
Aggregate Intrinsic Value, Granted | $
Number of Options, Vested	(442,532)
Weighted Average Exercise Price, Vested | $ / shares	$ 2.47
Aggregate Intrinsic Value, Vested | $
Number of Options Unvested, End of Period	273,599
Weighted Average Exercise Price Unvested, Ending of Period | $ / shares	$ 13.99
Average Remaining Contractual Term (years) Unvested, End of Period	7 years 3 months 29 days
Aggregate Intrinsic Value Unvested, End of Period | $
Number of Options, Expired	50,898
Employees [Member] | Stock Options [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Number of Options, Granted
Number of Options, Expired
Number of Options, Expired
ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Total Intrinsic Value | $
Non-Employees [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Number of Options Unvested, Beginning of Period	66,202
Weighted Average Exercise Price Unvested, Beginning of Period | $ / shares	$ 7.24
Average Remaining Contractual Term (years) Unvested, Beginning of Period	6 years 4 months 17 days
Aggregate Intrinsic Value Unvested, Beginning of Period | $
Number of Options, Granted
Weighted Average Exercise Price, Granted | $ / shares
Aggregate Intrinsic Value, Granted | $
Number of Options, Expired
Weighted Average Exercise Price, Expired | $ / shares
Number of Options, Vested	(55,757)
Weighted Average Exercise Price, Vested | $ / shares	$ 4.69
Aggregate Intrinsic Value, Vested | $
Number of Options Unvested, End of Period	10,445
Weighted Average Exercise Price Unvested, Ending of Period | $ / shares	$ 20.86
Average Remaining Contractual Term (years) Unvested, End of Period	6 years 3 months
Aggregate Intrinsic Value Unvested, End of Period | $
Number of Options, Expired
Non Employees [Member] | Stock Options [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Number of Options, Granted
Number of Options, Expired	(322)
Number of Options, Expired	322
ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Total Intrinsic Value | $

Equity-Based Compensation (Deta

Equity-Based Compensation (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Number of options granted	0	0
Stock-based compensation expense	$ 1,006	$ 346
Unrecognized equity-based compensation cost	$ 434	$ 442

Schedule of Available for Sale

Schedule of Available for Sale (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Marketable Securities [Line Items]
Amortized Cost	$ 16,335	$ 15,924
Gross Unrealized Gains/(Losses)	(200)	(47)
Fair Value	16,135	15,877
Marketable securities	16,135	15,877
Fair Value, 12 Months or More	16,335	15,423
Gross Unrealized Gains/(Losses), 12 Months or More	(200)	(47)
Fair Value, Less than 12 Months		501
Gross Unrealized Gains/(Losses), Less than 12 Months
US Treasury Notes [Member]
Marketable Securities [Line Items]
Amortized Cost	5,502	5,746
Gross Unrealized Gains/(Losses)	(76)	(47)
Fair Value	5,426	5,699
Marketable securities	5,426	5,699
Fair Value, 12 Months or More	5,502	5,245
Gross Unrealized Gains/(Losses), 12 Months or More	(76)	(47)
Fair Value, Less than 12 Months		501
Gross Unrealized Gains/(Losses), Less than 12 Months
U.S. Government Mortgage Backed Securities [Member]
Marketable Securities [Line Items]
Amortized Cost	4,401	4,890
Gross Unrealized Gains/(Losses)	288	(52)
Fair Value	4,689	4,838
Marketable securities	4,689	4,838
Fair Value, 12 Months or More	4,401	4,890
Gross Unrealized Gains/(Losses), 12 Months or More	288	(52)
Fair Value, Less than 12 Months
Gross Unrealized Gains/(Losses), Less than 12 Months
Corporate Debt Securities [Member]
Marketable Securities [Line Items]
Amortized Cost	6,432	5,288
Gross Unrealized Gains/(Losses)	(412)	52
Fair Value	6,020	5,340
Marketable securities	6,020	5,340
Fair Value, 12 Months or More	6,432	5,288
Gross Unrealized Gains/(Losses), 12 Months or More	$ (412)	52
Fair Value, Less than 12 Months
Gross Unrealized Gains/(Losses), Less than 12 Months

Marketable Securities (Details

Marketable Securities (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Marketable securities	$ 16,135	$ 15,877

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Compensation	$ 16	$ 2
Professional fees	180	124
Other expenses	177	316
Accrued expenses	$ 373	$ 442

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Land, buildings and improvements	$ 10,530	$ 10,547
Furniture, fixtures, and equipment	2,426	5,136
Total property and equipment	12,956	15,683
Less: accumulated depreciation	(6,811)	(9,210)
Property and equipment, net	$ 6,145	$ 6,473

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($) $ in Thousands	May 13, 2021	Mar. 16, 2018	Apr. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Acquired Finite-Lived Intangible Assets [Line Items]
Depreciation methods, description				Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three to thirty-nine years.
Proceeds from sale of property and equipment		$ 4,080	$ 245	$ 245
Lease description		concurrently entered into an agreement to lease the property back for ten years. The lease payments are initially $408,000 per year for two years through March 31,
Operating Leases, Rent Expense, Net		$ 408
Payments to Acquire Property, Plant, and Equipment				26	9
Gain (Loss) on Disposition of Property Plant Equipment			$ 216	$ 216
Property, Plant and Equipment [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Payments to Acquire Property, Plant, and Equipment	$ 4,732,637

Schedule of Patents, Trademark

Schedule of Patents, Trademark Rights (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Balance	$ 1,498	$ 1,151	$ 1,151
Acquisitions	365		573
Abandonments			(68)
Amortization	(80)	$ (67)	(158)
Balance	$ 1,783		$ 1,498

Schedule of Amortization of Pat

Schedule of Amortization of Patents and Trademarks (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 125
2022	137
2023	154
2024	180
2025	212
Thereafter	975
Total	$ 1,783	$ 1,498	$ 1,151

Patents (Details Narrative)

Patents (Details Narrative)	6 Months Ended
	Jun. 30, 2021
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	17 years

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)

Jul. 12, 2020

Jul. 07, 2020

Sep. 27, 2019

Jan. 28, 2019

Nov. 14, 2018

Oct. 17, 2018

Dec. 31, 2020

Aug. 31, 2020

Mar. 31, 2021

Jun. 30, 2020

Mar. 31, 2020

Jun. 30, 2021

Dec. 31, 2020

Mar. 16, 2018

Class of Stock [Line Items]

Subscription/exercise price

$ 0.3875

Common stock, shares authorized

350,000,000

350,000,000

350,000,000

350,000,000

Common stock shares with specific limitations and restrictions on usage

8,000,000

Common stock shares issued, value

$ 12,887,000

$ 15,016,000

$ 25,764,000

Warrant description

In addition, on March 25, 2020, the Representative’s Warrant was amended to permit exercise of such warrant to commence on March 30, 2020. These warrants were exercised on March 31, 2020, and an aggregate of 266,665 shares were issued upon exercise of this warrant for gross proceeds of approximately $264,000 and a $46,000 expense for the warrant modification.

Proceeds from warrants exercised

$ 264,000

Warrant modification.

$ 46,000

Common stock, shares outstanding

42,154,371

47,832,997

47,832,997

42,154,371

Equity Distribution Agreement [Member]

Class of Stock [Line Items]

Number of shares sold in transaction

5,665,731

20,444,807

Proceeds from sale of common stock, net of issuance costs

$ 13,301,526

$ 53,936,615

Underwriting fee amount

465,533

$ 1,888,727

Pre-funded Warrants [Member]

Class of Stock [Line Items]

Proceeds from warrants exercised

1,870,000

Warrant [Member]

Class of Stock [Line Items]

Proceeds from warrants exercised

$ 7,687,860

Alliance Global Partners, LLC [Member]

Class of Stock [Line Items]

Common stock shares issued, value

$ 7,148,310

Number of shares issued upon transaction

1,740,550

Alliance Global Partners, LLC [Member] | Warrants [Member]

Class of Stock [Line Items]

Number of warrant to purchase shares of common stock

8,888,860

Alliance Global Partners, LLC [Member] | Pre-funded Warrants [Member]

Class of Stock [Line Items]

Subscription/exercise price

$ 0.90

Proceeds from warrants

$ 7,200,000

Warrant description

Each Warrant sold with the shares of Common Stock represents the right to purchase one share of Common Stock at an exercise price of $0.99 per share. The Pre-Funded Warrants and Warrants were sold at a combined Offering price of $0.899, less underwriting discounts and commissions. The Pre-Funded Warrants were sold to purchasers whose purchase of shares of Common Stock in the Offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of the Company’s outstanding Common Stock immediately following the consummation of the Offering, in lieu of shares of Common Stock. Each Pre-Funded Warrant represents the right to purchase one share of Common Stock at an exercise price of $0.001 per share.

Maxim Group LLC [Member] | Equity Distribution Agreement [Member]

Class of Stock [Line Items]

Shares sales fee percentage

3.50%

3.50%

3.50%

Maximum [Member] | Alliance Global Partners, LLC [Member] | Representative Warrants [Member]

Class of Stock [Line Items]

Number of warrant to purchase shares of common stock

266,665

Directors, Officers and Employees [Member]

Class of Stock [Line Items]

Common stock shares issued, value

$ 500,000

$ 500,000

Rights [Member]

Class of Stock [Line Items]

Subscription/exercise price

$ 1,000

Common stock conversion price

$ 8.80

Proceeds from warrants

$ 4,700,000

Warrant [Member]

Class of Stock [Line Items]

Subscription/exercise price

$ 8.80

Warrants and Rights Outstanding, Term

5 years

Series A Junior Participating Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

250,000

Series B Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

732

725

732

Preferred stock par or stated value

$ 1,000

$ 1,000

$ 1,000

$ 1,000

Series B Convertible Preferred Stock [Member] | Rights [Member]

Class of Stock [Line Items]

Preferred stock value

$ 1,000

Preferred Stock [Member]

Class of Stock [Line Items]

Number of shares to be issued on conversion

114

Common Stock [Member]

Class of Stock [Line Items]

Common stock shares issued, value

$ 25,000

$ 50,000

$ 50,000

Number of shares issued upon transaction

10,730

21,700

27,501

Shares issued price per share

$ 2.33

Common Stock [Member] | Minimum [Member]

Class of Stock [Line Items]

Shares issued price per share

1.72

$ 2.26

$ 1.72

Common Stock [Member] | Maximum [Member]

Class of Stock [Line Items]

Shares issued price per share

$ 2.03

$ 2.35

$ 2.03

Board of Directors [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

5,000,000

Preferred stock par or stated value

$ 0.01

Number of common stock reserved for potential issuance

7,000,000

Number of options granted

26,324

Option exercise price per share

$ 9.68

Option vested years

10 years

Employees [Member]

Class of Stock [Line Items]

Number of options granted

23

Option exercise price per share

$ 9.68

Option vested years

10 years

Officers [Member]

Class of Stock [Line Items]

Number of options granted

27,570

400,000

Option exercise price per share

$ 9.68

Option vested years

1 year

1 year

Settlement of accounts payable

10 years

10 years

Officers [Member] | Minimum [Member]

Class of Stock [Line Items]

Option exercise price per share

$ 2.77

Officers [Member] | Maximum [Member]

Class of Stock [Line Items]

Option exercise price per share

$ 3.07

Employees [Member]

Class of Stock [Line Items]

Number of options granted

675,000

Option vested years

1 year

Settlement of accounts payable

10 years

Employees [Member] | Minimum [Member]

Class of Stock [Line Items]

Option exercise price per share

$ 1.85

Employees [Member] | Maximum [Member]

Class of Stock [Line Items]

Option exercise price per share

$ 1.96

Long-Term Debt (Details Narrati

Long-Term Debt (Details Narrative) - USD ($)	Jun. 19, 2020	May 29, 2020	Dec. 05, 2019	Aug. 05, 2019	Jun. 30, 2021	Jun. 30, 2020
CV Note [Member]
Short-term Debt [Line Items]
Interest expense debt					$ 0	$ 116,000
CV Note [Member] | Chicago Venture Partners, L.P. [Member]
Short-term Debt [Line Items]
Debt instrument, face amount				$ 2,635,000		1,985,000
Note interest rate				10.00%
Debt term				24 months
Proceeds from notes payable				$ 1,900,000
Debt instrument, redemption amount						650,000
Accrued interest payable		$ 220,000
Net payment of debt		1,795,000
Origination discount		369,000
Issuance costs		6,000
Gain (loss) on extinguishment of debt		$ 66,000
AS Note [Member]
Short-term Debt [Line Items]
Interest expense debt					$ 0	$ 106,000
AS Note [Member] | Atlas Sciences L.P. [Member]
Short-term Debt [Line Items]
Debt instrument, face amount	$ 2,175,000		$ 2,175,000
Note interest rate			10.00%
Debt term			24 months
Accrued interest payable	122,000
Origination discount	376,000
Issuance costs	7,000
Gain (loss) on extinguishment of debt	76,000
Notes payable	$ 1,838,000

Schedule of Assumptions to Esti

Schedule of Assumptions to Estimate Fair Value of Warrants (Details)	Jun. 30, 2021$ / shares	Dec. 31, 2020$ / shares
August 2016 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 2.15	$ 1.79
August 2016 Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	82.50	82.50
August 2016 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	0.02	0.09
August 2016 Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	2 months 1 day	8 months 1 day
August 2016 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	35	75
August 2016 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage
February 2017 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 2.15	$ 1.79
February 2017 Warrants [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	30.25	30.25
February 2017 Warrants [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	33	33
February 2017 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage		0.12
February 2017 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	0.08
February 2017 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	0.10
February 2017 Warrants [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	1 year 1 month 2 days	1 year 6 months 29 days
February 2017 Warrants [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	1 year 1 month 6 days	1 year 7 months 6 days
February 2017 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	80	130
February 2017 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage
June 2017 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 2.15	$ 1.79
June 2017 Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	27.50	27.50
June 2017 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	0.07	0.11
June 2017 Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	11 months 1 day	12 years 5 months 1 day
June 2017 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	75	135
June 2017 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage
August 2017 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 2.15	$ 1.79
August 2017 Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	19.80	19.80
August 2017 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	0.06	0.11
August 2017 Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	8 months 4 days	1 year 2 months 4 days
August 2017 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	70	110
August 2017 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage
April 2018 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 2.15	$ 1.79
April 2018 Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	17.16	17.16
April 2018 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	0.32	0.16
April 2018 Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	2 years 3 months 25 days	2 years 9 months 21 days
April 2018 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	140	105
April 2018 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage
March 2019 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 2.15	$ 1.79
March 2019 Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	8.80	8.80
March 2019 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	0.29	0.19
March 2019 Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	2 years 8 months 8 days	3 years 2 months 8 days
March 2019 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage	135	105
March 2019 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input Percentage

Schedule of Range of Probabilit

Schedule of Range of Probabilities (Details)	6 Months Ended
	Jun. 30, 2021
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	0.50%
Weighted Average [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	1.00%
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	5.00%

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 16,135	$ 15,877
Redeemable warrants	209	180
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	16,135	15,877
Redeemable warrants
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Redeemable warrants
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Redeemable warrants	$ 209	$ 180

Schedule of Changes in Level 3

Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis (Details) - Redeemable Warrants [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Balance at beginning	$ 180
Fair value adjustments	29
Balance at ending	$ 209

Fair Value (Details Narrative)

Fair Value (Details Narrative)	6 Months Ended
	Jun. 30, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Sale of stock, description	The Company also has certain warrants with a cash settlement feature in the unlikely occurrence of a Fundamental Transaction, namely (1) a merger or consolidation with another person; (2) sale of substantially all of its assets; (3) holders of common stock sell 50% or more of outstanding shares; (4) the Company effects an exchange of all its securities for other securities, cash or property, and (5) the Company effects a stock purchase agreement or business combination for more than 50% of outstanding shares.
Floor rate used as proxy for future volatility percentage	100.00%
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input percentage	0.00%

Financing Obligation Arising _2

Financing Obligation Arising from Sale Leaseback Transaction (Details Narrative) - USD ($)	May 13, 2021	Mar. 16, 2018	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from Sale of Buildings		$ 4,080,000
Lease and property agreement description		lease the property back for ten years at $408,000 per year for two years through March 31, 2020. The lease payments will increase 2.5% per year for the next three years through March 31, 2023 and the lease payments will increase 3% for the remaining five years through March 31, 2028.
Lease of rent expenses		$ 408,000
Number of domestic subsidiaries		5 years
Warrant to purchase of common stock		3,225,806
Warrant exercise price per share		$ 0.3875
Warrant closing price, percentage		125.00%
Warrant owning excess percentage		4.99%
Repurchase of property	$ 4,732,637,000
Financing Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Extinguishment of financing obligation and note payable			$ 2,701,460
Financing Interest Expense				$ 19,000	$ 31,000

Schedule of Operating lease Fut

Schedule of Operating lease Future Payments (Details) $ in Thousands	Jun. 30, 2021USD ($)
Leases [Abstract]
2021	$ 39
2022	50
2023	40
2024	46
2025	16
Thereafter	7
Less imputed interest	(41)
Total	$ 157

Leases (Details Narrative)

Leases (Details Narrative) $ in Thousands	May 01, 2019USD ($)ft²	Jun. 13, 2018USD ($)ft²	Mar. 16, 2018USD ($)	Jun. 01, 2015USD ($)	Jun. 30, 2021USD ($)ft²	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Entity Listings [Line Items]
Base rent per month			$ 408
Rentable area | ft²					30,000
weighted-average remaining term					3 years 2 months 19 days
Right of use asset					$ 157		$ 179
Operating lease liability					157
Rent expenses					$ 22	$ 21
Minimum [Member]
Entity Listings [Line Items]
Remaining lease terms					6 months
Maximum [Member]
Entity Listings [Line Items]
Remaining lease terms					4 years
Lease Agreement [Member] | Fraser Advanced Information Systems [Member]
Entity Listings [Line Items]
Lease agreement term.				5 years
Lease commenced date				Sep. 14, 2020
Lease Agreement [Member] | Fraser Advanced Information Systems [Member] | First Year [Member]
Entity Listings [Line Items]
Base rent per month				$ 1,415
Lease Agreement [Member] | SML FL Holdings LLC [Member]
Entity Listings [Line Items]
Lease agreement term.		6 years
Lease commenced date		Jul. 1, 2018
Rentable area | ft²		3,000
Percentage of base rent		3.00%
Lease Agreement [Member] | SML FL Holdings LLC [Member] | First Year [Member]
Entity Listings [Line Items]
Base rent per month		$ 2,100
Lease Agreement [Member] | SML FL Holdings LLC [Member] | Sixth Year [Member]
Entity Listings [Line Items]
Base rent per month		$ 2,785
Lease Agreement [Member] | 604 Associates LLC [Member]
Entity Listings [Line Items]
Lease agreement term.	3 years
Lease commenced date	May 1, 2019
Base rent per month	$ 1,500
Rentable area | ft²	3,000